SCHEMBL1759313

SCHEMBL1759313

COC(=O)c1ccnc(C(C)=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.58
KDM6B O15054 2/20 0.58
KDM5C P41229 2/20 0.58
KDM4C Q9H3R0 2/20 0.58
KDM2A Q9Y2K7 2/20 0.58
KDM3A Q9Y4C1 2/20 0.58
ALOX15 P16050 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
JMJD6 Q6NYC1 1/20 0.51
HTT P42858 2/20 0.47
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.47
KDM5B Q9UGL1 2/20 0.47
TET3 O43151 1/20 0.47
KDM4A O75164 1/20 0.47
BBOX1 O75936 1/20 0.47
KDM5A P29375 1/20 0.47
ASPH Q12797 1/20 0.47
KDM4D Q6B0I6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378954 1.00 KDM4E (0.58) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL70350 0.89 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL30065796 0.89 KDM4E (0.62) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL30779113 0.86 KDM4E (0.68) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL30236802 0.86 KDM4E (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL475565 0.86 KDM4E (0.68) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL4939178 0.86 KDM4E (0.50) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL13950719 0.84 KDM4E (0.57) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL1759324 0.84 KDM4E (0.57) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL25342222 0.83 KDM4E (0.53) KDM4EKDM6BKDM5CKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
EP-4676918-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS Nanjing Immunophage Biomedical Co., Ltd. (CN) 2026-01-14 EP disclosed
EP-4626896-A1 POLYELECTROPHILIC METALATED HETEROCYCLES DERIVED FROM 2-(PYRIDIN-2-YL)IMIDAZO[1,2-A]PYRIDINE AND USE THEREOF AS CHEMOTHERAPEUTIC AGENTS Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) 2025-10-08 EP disclosed
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 US disclosed
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 EP disclosed
WO-2024249950-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION, INC. (US) 2024-12-05 WO disclosed
CN-118974036-A Inhibitors of RAF kinase 皮埃尔法布雷医药公司 2024-11-15 CN disclosed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 WO disclosed
WO-2024208303-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2024-10-10 WO disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 EP disclosed
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. 2013-11-07 US disclosed
US-8507681-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2013-08-13 US disclosed
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC. (US) 2013-01-31 US disclosed
US-8288405-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-10-16 US disclosed
EP-2499139-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
EP-2499140-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2012-09-19 EP disclosed
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-09-06 US disclosed
WO-2011058473-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
WO-2011058474-A1 N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2011-05-19 WO disclosed
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110111046-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1385/4885KDM6B 3205/4885KDM5C 1907/4885
US-20130296319-A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS ACACA, PC, ACACB KDM4E 1311/4885KDM6B 3056/4885KDM5C 1837/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 KDM4E 680/4885KDM6B 128/4885KDM5C 316/4885
US-20130030181-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1385/4885KDM6B 3205/4885KDM5C 1907/4885
US-20120225900-A1 N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS ACACA, PC, ACACB KDM4E 1533/4885KDM6B 3235/4885KDM5C 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.